Volume 27, Issue 2 pp. 65-67
Therapeutic Hotline

Eyelid milia en plaque: a treatment challenge with a new CO2 fractional laser

Stefania Tenna

Corresponding Author

Stefania Tenna

Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University, Rome, Italy

Address correspondence and reprint requests to: Stefania Tenna, MD, PhD, Assistant Professor, Plastic Surgery Unit, “Campus Bio-Medico” University, via Alvaro del Portillo 200, 00128 Rome, Italy, or email: [email protected].Search for more papers by this author
Angela Filoni

Angela Filoni

Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University, Rome, Italy

Search for more papers by this author
Calogero Pagliarello

Calogero Pagliarello

Dermatology Unit, Campus Bio-Medico University, Rome, Italy

Search for more papers by this author
Mauro Paradisi

Mauro Paradisi

Dermatology Unit, Campus Bio-Medico University, Rome, Italy

Search for more papers by this author
Paolo Persichetti

Paolo Persichetti

Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University, Rome, Italy

Search for more papers by this author
First published: 02 May 2013
Citations: 3
Financial Disclosure: The authors have indicated no significant interest with commercial supporters.

Abstract

Milia en plaque (MEP) is an uncommon finding characterized by numerous tiny milia within an erythematous area.

Despite its benign and asymptomatic nature, MEP raises cosmetic concerns; moreover, the available treatment modalities for MEP are limited. In view of the few cases described in the literature, no consensus has been reached, with respect to the optimal treatment for MEP, and the choice of therapy should be individualized.

We report a case of eyelid milia en plaque successfully treated with a new CO2 fractional laser that is able to ensure superficial ablation of the epidermis remodeling tissue in-depth, with minimal thermal damage and extremely rapid recovery time.

The results obtained after only two treatments were good, no scarring or dyschromic changes have been registered. At 1 year, just few recurrent milia were present.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.